Introducing peanut products into the diets of infants at high risk of developing peanut allergy was safe and led to an 81% reduction in the subsequent allergy development, reports a new study.
Meda announced that the Food and Drug Administration (FDA) has approved Dymista (azelastine HCl and fluticasone propionate) for the relief of symptoms of seasonal allergic rhinitis (SAR) in patients ages 6-11 who require treatment with both components.
Data from a Phase 2b trial showed that patients with peanut allergy using Viaskin Peanut (DBV Technologies) showed significant improvement using this epicutaneous immunotherapy (EPIT) after one year.
Loratadine, an antihistamine found in over-the-counter allergy medicines, may be able to help kill the bacteria associated with Lyme disease (Borrelia burgdorferi).
A new oral therapy that combines a probiotic and peanut protein appears to be a successful immunotherapy for peanut allergy, based on a study conducted by researchers at Murdoch Childrens Research Institute at the Royal Children's Hospital in Australia.
The Food and Drug Administration (FDA) is warning about a slightly increased risk of cardiovascular and cerebrovascular events among patients being treated with Xolair (omalizumab; Genentech and Novartis) for asthma compared to those not treated with Xolair.
Vicks announced the launch of QlearQuil, a line of over-the-counter (OTC) products for the treatment of sinus and allergy symptoms.
The Food and Drug Administration (FDA) has issued an alert regarding an ingredient commonly found in gluten-free products that may cause anaphylaxis in patients with a legume allergy.
GlaxoSmithKline announced that the FDA has approved Flonase Allergy Relief (fluticasone propionate 50mcg spray) as a once-daily over-the-counter (OTC) treatment indicated for symptoms of seasonal and perennial allergic and nonallergic rhinitis in patients ≥4 years of age
Greer laboratories announced the launch of Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.
Ranbaxy has announced a voluntary recall of 29,790 blister packs of an over-the-counter (OTC) allergy medication in the U.S. after an unacceptable number of blister defects were identified.
The FDA announced the approval of Ragwitek (Ambrosia artemisiifolia; Merck), the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis.
Merck announced that the FDA has approved Grastek (Timothy grass pollen allergen extract) Tablet for Sublingual Use as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
Greer Laboratories announced that the FDA has approved Oralair sublingual allergy immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
Genentech announced that the FDA has approved Xolair (omalizumab) injection for the treatment of chronic idiopathic urticaria (CIU).
Allergy prevalence is uniform across varying regions in the U.S, except in children ≤5 years old, according to an NIH study.
Adjuvant high-dose vitamin D3 is beneficial for patients with chronic urticaria.
"Talking" medical devices and apps, among other techy health-focused inventions, can help people manage everyday wellness routines, such as taking pills and checking blood sugar levels, as well as dire medical circumstances.
Sanofi and its consumer healthcare division Chattem announced that Nasacort (triamcinolone acetonide) Allergy 24hr Nasal Spray is now available over-the-counter (OTC).
Peanut oral immunotherapy (OIT) is efficacious for desensitization of children with peanut allergy.
Early allergen exposure may increase tolerance and lowers risk of childhood food allergy.
The delay of solid foods until ≥17 weeks of age and continued breastfeeding when cow's milk protein is introduced to infants' diets correlate with a reduced likelihood of food allergies.
President Obama signed a new law meant to increase the availability of life-saving epinephrine in U.S. schools on Wednesday.
Merck announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) to treat the underlying cause of allergic rhinitis.
Non-celiac wheat sensitivity (NCWS) may be a non-immunoglobulin E-mediated food allergy.
Mothers' receipt of immunotherapy during pregnancy may reduce the risk of any type of allergy in offspring.
Multiple chronic conditions are associated with worse health in terms of activities of daily living and health-related quality of life in older adults.
Patients with egg allergy face no increased danger from receiving injectable inactivated influenza vaccine as a single dose.
Childhood food allergies result in significant direct medical costs for the U.S. health care system and even larger total costs for families of food-allergic children.
Probiotic exposure in early life may reduce total immunoglobulin E level (IgE) and protect against atopic sensitization, but does not seem to protect against asthma/wheezing.
AidaPak is initiating a voluntary recall for strip packs at the hospital/user level after learning of possible incorrect labeling.
Children treated successfully for milk allergies with oral immunotherapy lose tolerance after several years.
About a fifth of patients who have received a spinal injection of fungus-contaminated methylprednisolone but have not sought medical care are likely to be infected.
Amedra announced the relaunch of Adrenaclick (epinephrine) auto-injector for the emergency treatment of anaphylaxis.
Atriphen has been recalled due to the possibility of causing a severe allergic reaction from two undeclared allergens.
The FDA has accepted for review the Biologics License Application for ragweed pollen sublingual allergy immunotherapy tablet.
Parental sucking of their infant's pacifier is associated with a reduced risk of allergy development.
For U.S. children aged younger than 18 years, the prevalence of allergies increased from 1997-2011, with age, race/ethnicity, and income all affecting the prevalence.
Saratoga Therapeutics recalled 900 bottles of ebA Multivitamin Supplement because they may contain undeclared milk components such as milk protein(s) and lactose.
MyAllergyTest, a lab-based quantitative IgE and allergy diagnostic, is the first FDA-approved at-home test that allows allergy patients to test themselves against 10 key allergens.
Immunoglobulin E antibody specific for galactose-α1,3-galactose, which is associated with delayed anaphylaxis and urticaria that occurs several hours after eating beef, pork, or lamb, has been identified in children reporting idiopathic anaphylaxis or urticaria.
The FDA has approved the New Drug Application for Tris Pharma's Karbinal Extended-Release Oral Suspension. Karbinal is used to treat seasonal and perennial allergic rhinitis in children 2 years of age and older.
After visible particulates were found in product vials, Pallimed Solutions is voluntarily recalling all sterile compounds dispensed since January 1, 2013. Particulate matter can potentially damage or obstruct blood vessels.
Merck's Biologics License Application was accepted for its investigational Timothy grass pollen allergy immunotherapy tablet (AIT). In March, the company submitted a BLA for its investigational ragweed pollen AIT.
Complications linked to tattoos and tattoo inks include allergic reactions, serious infections, and reactions that can be mistaken for skin cancer.
Genentech and Novartis announced the results from a Phase 3 study, ASTERIA II, which showed that omalizumab, met its primary endpoint in patients with moderate to severe chronic idiopathic urticaria (CIU), who remained symptomatic despite treatment with approved H1 antihistamine doses.
Acupuncture produces statistically significant improvements in disease-specific quality of life and reduces antihistamine use in patients with seasonal allergic rhinitis (SAR), although further study is required to determine whether these results are clinically significant.
Sanofi announced that Auvi-Q (epinephrine injection) is now available.
For children with food allergy, bullying is common, and correlates with decreased quality of life and increased distress for children and their parents.
Just over half of children with hen egg allergies can tolerate baked eggs in an oral food challenge (OFC); and more than a quarter of children over the age of 10 with food allergies develop tolerance.
People with both hay fever and asthma have a modestly reduced risk of dying from colorectal cancer.
Local allergic rhinitis (LAR) is prevalent among patients with rhinitis, affecting about one in four, and is often associated with childhood onset and persistent, severe conjunctivitis and/or asthma.
Perceived stress correlates with an increased risk of adult-onset asthma, allergic rhinitis, and atopic dermatitis as well as asthma medication use.
Nearly one-third of parent-reported food allergies are not formally diagnosed by a physician
When a drug switches from prescription-only to over-the-counter (OTC) there is a shift in the direct-to-consumer advertising (DTCA), with less presentation of potential harms and frequent omission of identification by generic names.
Patients with unpredictable and recurring attacks of acute hereditary angioedema (HAE) may be effectively treated with ecallantide, with relapse occurring in a small proportion of patients and little evidence of rebound.
Mylan Specialty announced the EpiPen4Schools program, which offers four free EpiPen (epinephrine 0.3mg; DEY Pharma) or EpiPen Jr (epinephrine 0.15mg; DEY Pharma) Auto-Injectors upon qualification.
Sanofi announced that the FDA has approved Auvi-Q (epinephrine injection) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.
There appears to be an inverse relationship between elevated allergy biomarker levels (immunoglobulin E [IgE]) and the risk of developing glioma, which is detectable many years before tumor diagnosis.
Individuals who have been bitten by the lone star tick may develop immunoglobulin E (IgE) to the carbohydrate galactose-α-1,3-galactose (alpha-gal), which puts them at risk for delayed anaphylaxis after consumption of meat containing alpha-gal on glycoproteins or glycolipids.
Sunovion announced the nationwide availability of Zetonna (ciclesonide) Nasal Aerosol, 74mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies.
Concentrations of several fragrance allergens applied to test chambers well in advance of patient testing may be reduced by >20% within hours when stored at room temperature.
Oral immunotherapy represents a promising therapeutic intervention for children with egg allergy.
Studies investigating the effect of diet on the development of childhood asthma and allergies generally have substantial shortcomings with regard to how they handle confounding and effect modification.
Prenatal exposure to butylbenzyl phthalate (BBzP), as assessed by increased concentrations of monobenzyl phthalate (MBzP) in the urine, is associated with an increased risk of early-onset eczema in offspring.
For infants with documented or likely allergies to milk or eggs, most allergic reactions result from accidental exposures.
From 2002-2010 there was a 7% decrease in outpatient pediatric prescription medication utilization, due in part to a decrease in antibiotics and allergy medication prescriptions.
The prevalence of childhood food allergy is associated with urban/rural status, even after adjusting for confounding variables.
Roadside ragweed pollen exposed to pollution from heavy automobile traffic is more allergenic than pollen from similar plants found near less-traveled roads or in vegetated areas.
Meda announced that the FDA has approved Dymista (azelastine HCl and fluticasone propionate) nasal spray for the treatment of seasonal allergic rhinitis.
Children born in the fall have an increased risk of food allergy, with a significantly increased risk seen only for Caucasians and those with eczema.
A novel lipocalin dog allergen has been identified in nearly 40% of dog-sensitized individuals, which cross-reacts with lipocalins from cat and horse.
American Regent is conducting a nationwide voluntary recall of Epinephrine Injection, 1:1000, 1mL ampules (NDC #0517-1071-25; Lot #1395; Exp Date: July 2012).
Eczema, asthma, and rhinitis occur in 58 percent of children; 7.5 percent have comorbidities
Teva announced that the FDA has approved QNASL (beclomethasone dipropionate) Nasal Aerosol, a non-aqueous, "dry" nasal aerosol corticosteroid for the treatment of seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
An immunologically-enhanced subcutaneous immunotherapy (SCIT) formulation, with an optimized ratio of allergen to adjuvant, induces a significant immunologic response with acceptable safety when injected every three to four days compared with standard weekly injections.
Larger neonates born at term to mothers with a history of asthma are more likely to develop asthma by age 7, but are not more likely to have allergic sensitization or atopic dermatitis.
The prevalence of asthma, hay fever, and allergic sensitization is significantly lower among the Amish population than among Swiss children.
Asthma patients with a history of food allergy are less likely than similar individuals without asthma to fail an oral food challenge.
Teva announced findings from four Phase 3 clinical studies that examined the efficacy and safety profile as well as impact on quality of life (QoL) of QNASL (beclomethasone dipropionate [BDP]) Nasal Aerosol, a non-aqueous, "dry" nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
Merck announced the results from its Phase 3 study of its investigational Ambrosia artemisiifolia (ragweed) allergy immunotherapy tablet (AIT) for ragweed pollen allergy.
Eczema, asthma, and rhinitis affect >50% of children up to age 12.
Acupuncture and cetirizine both reduce type I hypersensitivity itch better than placebo or no intervention.
A woman's prenatal exposure to high stress and dust mite allergens may interact to affect the immune system of her offspring.
The FDA has notified healthcare professionals and consumers that Insight Pharmaceuticals has recalled one lot of Nostrilla Nasal Decongestant (Oxymetazoline HCl nasal spray) because it may contain the bacteria Burkholderia cepacia.
Dey Pharma announced that it will be supplying only EpiPen 2-Pak and EpiPen Jr 2-Pak (epinephrine auto-injector) and transitioning away from the EpiPen and EpiPen Jr single packages.
Teva announced that the FDA has accepted its New Drug Application (NDA) for BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) after its submission in May 2011.
American Regent is conducting a voluntary nationwide recall of one lot of calcium gluconate injection 10% because some of the vials may contain silicone particles.
Meda announced new results from its Phase 3 study of Dymista (azelastine HCl and fluticasone propionate; Meda) nasal spray for the treatment of allergic rhinitis.
The FDA has accepted for filing the NDA for Dymista (azelastine HCl and fluticasone propionate; Meda) nasal spray for the treatment of allergic rhinitis.
Hawthorn Pharmaceuticals announced that Arbinoxa (carbinoxamine) tablets and oral solution are available for the treatment of allergic (seasonal and perennial) and vasomotor rhinitis, conjunctivitis, urticaria, angioedema, and reactions to blood.
Meda announced positive results from its Phase 3 trial of Dymista (azelastine HCl and fluticasone propionate) nasal spray in patients with seasonal allergic rhinitis
American Regent announced a voluntary nationwide recall of concentrated sodium chloride injection, bacteriostatic sodium chloride injection, and dexamethasone sodium phosphate injection.
Santarus and Pharming announced initiation of their Phase 3b study of RHUCIN (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with hereditary angioedema.
The FDA is reminding healthcare professionals about the safe use of non-sterile alcohol prep pads to clean and disinfect the surface of the skin.
The FDA has approved sanofi-aventis' Allegra and Children's Allegra (fexofenadine) and Allegra-D (fexofenadine and pseudoephedrine) product lines to be marketed over-the-counter.
The National Institute of Allergy and Infectious Diseases (NIAID) Issues issued a new clinical practice guideline to assist healthcare professionals in the diagnosis and management of food allergy.
Shire announced topline results from FAST-3, the largest of its Phase 3 trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).
McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.
Procter & Gamble announced a voluntary nationwide recall of Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray (oxymetazoline HCl).
- Recall of Two IV Antibiotics Announced
- Five Things ID Experts Want You to Know Before You Prescribe an Antibiotic
- What's Changed in Immunization Recommendations From CDC Advisory Committee
- Peanut Allergy Patch Shows Promise in Latest Study
- IUD Approval Gives Women New Long-Acting Birth Control Option
- Limit Daily Use of Headphones, Warns WHO
- Sleep Deprivation Could Derail Healthy Eating Habits
- Not Enough COPD Patients Receiving Maintenance Tx, Research Suggests
- Harvoni for HCV Genotype 4, HIV Co-Infection Assessed in New Research
- Combo Therapy for HCV, HIV Co-Infection: New Data on Sustained Virologic Response